Cancer and venous thromboembolism: A multidisciplinary approach

Clinical Laboratory

Volumn 49, Issue 11-12, 2003, Pages 615-623

  Sørensen, Henrik Toft ^a,d   Johnsen, Søren P ^a,d   Nørgård, Bente ^a,d   Zacharski, Leo R ^b,c   Baron, John A ^c  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b VA MEDICAL CENTER   (United States)

^c DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^d AALBORG UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Anti thrombotic agents; Cancer; Epidemiology; Screening; Therapy; Thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTINEOPLASTIC AGENT; CELECOXIB; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; WARFARIN;

ANIMAL MODEL; ANTICOAGULATION; ANTINEOPLASTIC ACTIVITY; BLOOD VESSEL INJURY; CANCER; CANCER PATIENT; CANCER RISK; CANCER SCREENING; CANCER SURVIVAL; CLINICAL TRIAL; DISEASE ASSOCIATION; DRUG POTENCY; HEALTH PROGRAM; HISTOPATHOLOGY; HUMAN; HYPERCOAGULABILITY; NONHUMAN; PATIENT CARE; PREDICTION; PROGNOSIS; RETROSPECTIVE STUDY; REVIEW; RISK ASSESSMENT; SURVIVAL RATE; THROMBOEMBOLISM; VEIN THROMBOSIS; VENOUS STASIS;

ANTICOAGULANTS; HUMANS; NEOPLASMS; PROGNOSIS; THROMBOEMBOLISM; VENOUS THROMBOSIS;

ANIMALIA;

EID: 0345601780     PISSN: 14336510     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (67)

1. Plegmasia alba dolens. In: Trousseau A. Lectures on clinical medicine, delivered at the Hotel-Dieu, Paris. Cormack JR, trans. London: New Sydenham Society, 1872, pp 281-295
2. Ambrus JL, Ambrus CM, Mink IB, Pickren JW. Causes of death in cancer patients. J Med 1975; 6: 61-64
3. Dhami MS, Bona RD. Thrombosis in patients with cancer. Postgraduate Med 1993; 93: 131-140
4. Green KB, Silverstein RL. Hypercoagulability in cancer. Hematol Oncol Clin North Am 1996; 10: 499-530
5. Donati MB. Cancer and thrombosis. Haemostasis 1994; 24: 128-131
6. Gore JM, Appelbaum JS, Greene HL, Dexter L, Dalen JE. Occult cancer in patients with acute pulmonary embolism. Ann Intern Med 1982; 96: 556-560
7. Goldberg RJ, Seneff M, Gore JM et al. Occult malignant neoplasm in patients with deep venous thrombosis. Arch Intern Med 1987; 147: 251-253
8. Griffin MR, Stanson AS, Brown ML et al. Deep venous thrombosis and pulmonary embolism. Risk of subsequent malignant neoplasms. Arch Intern Med 1987; 147: 1907-1911
9. Nordstrom M, Lindblad B, Anderson H, Bergquist D, Kjellstrom T. Deep venous thrombosis and occult malignancy: an epidemiological study. Br Med J 1994; 308: 891-894
10. Aderka D, Brown A, Zelikovski A, Pinkhas J. Idiopathic deep venous in an apparently healthy patient as an premonitory sign of occult cancer. Cancer 1986; 57: 1846-1849
11. Monreal M, Salvador R, Soriano V, Sabria M. Cancer and deep vein thrombosis. Arch Intern Med 1988; 148; 485
12. Monreal M, Lafoz E, Casals A et al. Occult cancer in patients with deep venous trombosis: a systematic approach. Cancer 1991; 67: 541-545
13. Prandoni P, Lensing AWA, Büller HR et al. Deep-vein thrombosis and the incidence of subsequent symptomatic cancer. N Engl J Med 1992; 327: 1128-1133
14. Monreal M, Casals A, Boix J, Olazabal A, Montserrat E, Ribas Mundo M. Occult cancer in patients with acute pulmonary embolism. A prospective study. Chest 1993; 103: 816-819
15. Bastounis EA, Karayannakis AJ, Makri GG, Alexiou D, Papalambros EL. The incidence of occult cancer: a prospective study. J Intern Med 1996; 239: 153-156
16. Ahmed Z, Mohuddin Z. Deep vein thrombosis as a predictor of cancer. Angiology 1996; 47: 261-265
17. Monreal M, Fernandez-Llamazares J, Perandreu J, Urrutia A, Sahuquillo JC, Contel E. Occult cancer in patients with venous thromboembolism: which patients, which cancers. Thromb Haemostas 1997; 78: 1316-1318
18. Achkar A, Laaban JP, Horellou MH, Rabbat A, Conard J, Nataf J. Prospective screening for occult cancer in pateints with venous thromboembolism. Thromb Haemostas 1997 (Suppl); OC-1564
19. Hettiarachchi RJK, Lok J, Prins MH, Büller HR, Prandoni P. Undiagnosed malignancy in patients with deep vein thrombosis. Cancer 1998; 83: 180-185
20. Rajan R, Levine M, Gent M et al. The occurrence of subsequent malignancy in patients presenting with deep vein thrombosis: results from a historical cohort study. Thromb Haemost 1998; 79: 19-22
21. Baron JA, Gridley G, Weiderpass E, Nyren O, Linet M. Venous thromboembolism and cancer. Lancet 1998; 351: 1077-1080 [Erratum, Lancet 2000; 355:758.]
22. Sørensen HF, Mellemkjær, Steffensen FH, Olsen JH, Nielsen GL. The risk of diagnosis of cancer after primary deep venous thrombosis or pulmonary embolism. N Engl J Med 1998; 338: 1169-1173
23. Piccioli A, Prandoni P, Ewenstein BM, Goldhaber SZ. Cancer and venous thromboembolism. Am Heart J 1996; 132: 850-855
24. Prandoni P, Piccioli A, Girolami A. Cancer and venous thromboembolism: an overview. Haematologica 1999; 84: 437-445
25. Salzman EW, Hirsh J: Epidemiology, pathogenesis, and natural history of venous trombosis. In Colman RW, Hirsh J, Marder VJ, Salzman EW (eds): Hemostasis and thrombosis: basic principles and clinical practice. JB Lippincott, Philadelphia, USA, 1993, pp 1275-1298
26. Johnson MJ. Bleeding, clotting and cancer. Clin Oncol 1997; 9: 294-301
27. Zacharski LR, Wojtukiewicz MZ, Constantini V, Ornstein DL, Memoli VA. Pathways of coagulation/fibrinolysis activation in malignancy. Semi Thromb Hemostat 1992; 18: 104-116
28. Nand S, Fisher SG, Salgia R, Fisher RI. Haemostatic abnormalities in untreated cancer. Incidence and correlation with thrombotic haemorrhagic complications. J Clin Oncol 1987; 5: 1998-2003
29. Zuckerman E, Toubi E, Golan TD, et al. Increased thromboembolic incidence in anti-cardiolipin-positive patients with malignancy. Br J Cancer 1995; 72: 447-451
30. Prandoni P, Lensing AW, Cogo A et al. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med 1996; 125: 1-7
31. Carson JL, Kelley MA, Duff A et al. The clinical course of pulmonary embolism. N Engl J Med 1992; 326: 1240-1245
32. Sørensen HT, Mellemkjær L, Olsen JH, Baron JA. Prognosis of cancers associated with venous thromboembolism. N Engl J Med 2000; 343: 1846-1850
33. Schulman S, Lindmarker P. Incidence of cancer after prophylaxis with warfarin against recurrent venous thromboembolism. N Engl J Med 2000; 342: 1953-1958
34. Buller H, Cate JWT. Primary venous thromboembolism and cancer screening. N Engl J Med 1998: 17: 1221-1222
35. Piccioli A, Lensing AWA, Prandoni P. Screening for occult malignancy in patients with idiopathic venous thromboembolism. Thromb Haemost 1997(suppl):PS-489
36. Piccioli A, Prandoni P. Venous Thromboembolism as First Manifestation of Cancer. Acta Haematol. 2001; 106(1-2):13-17
37. Otten HM, Prins MH. A number to screen and cost-effectiveness analysis of the SOMIT-data. Haemostasis 2001;31 Suppl 1:40-42
38. Ornstein DL, Zacharski LR. The use of heparin for treating human malignancies. Haemostasis 1999; 29 (suppl 1): 48-60
39. Jänne PA, Mayer RJ. Chemoprevention of colorectal cancer. N Engl J Med 2000; 342: 1960-1968
40. Goerner A. The influence of anticlotting agents on transplantation and growth of tumor tissue. J Lab Clin Med 1930; 16: 369-372
41. Hejna M, Raderer M, Zielinski CC. Inhibition of metastases by anticoagulants. J Natl Cancer Inst 1999; 91: 22-36
42. Kingston R, Fielding J, Palmer M. Peri-operative heparin: A possible adjuvant to surgery in colo-rectal cancer ? Int J Colorect Dis 1993; 8: 111-115
43. Tongren S, Rieger A. The influence of heparin and curable resection on the survival of colon cancer. Acta Chir Scand 1983; 149: 427-429
44. Kakkar A, Hedges A, Williamson R, Kakkar V. Perioperative heparin therapy inhibits late death from metatstatic cancer. Int J Oncol 1995; 6: 885-888
45. Elias E, Shulka S, Mink I. Heparin and chemoterapy in the management of inoperable lung cancer. Cancer 1975; 36: 129-136
46. Lebeau B, Chastang C, Brechot J-M et al. Subcutaneous heparin treatment increases survival in small cell lung cancer. Cancer 1994; 74: 38-45
47. Lensing A, Prins M, Davidson B, Hirsh J. Treatment of deep venous thrombosis with low molecular weight heparins. A meta-analysis. Arch Intern Med 1995; 155: 601-607
48. Siragusa S, Cosmi B, Piovella F, Hirsh J, Ginsburg J. Low-molecular-weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: Results of a meta-analysis. Am J Med 1996; 100: 269-277
49. Hettiarachchi RJK, Smorenburg SM, Ginsberg J, Levine M, Prins MH, Büller HR. Do heparins do more than just treat thrombosis? The influence of heparins on cancer spread. Thromb Haemost 1999; 82: 947-952
50. von Tempelhoff GF, Dietrich M, Neimann F, Schneider D, Hommel G, Heilmann L. Blood coagulation and thrombosis in patients with ovarian malignancy. Thromb Haemost 1997; 77: 456-461
51. von Tempelhoff GF, Harenberg J, Niemann F, Hommel G, Kirkpatrick CJ, Heilmann L. Effect of low molecular heparin (Certoparin) versus unfractionated heparin on cancer survival following breast and pelvic cancer surgery: a prospective randomized double-blind trial. Int J Oncol 2000; 16: 815-824
52. Kakkar AK, Kadziola Z, Williamson RCN, Levine MN, Low V, Lemoine NR. Low molecular weight heparin therapy and survival in advanced cancer. [abstract]. Blood 2002; 100: 557a
53. Klerk CPW, Smorenburg SM, Otten JMMB, Büller HR. Malignancy and low molecular weight-heparin therapy: The MALT trial. [abstract]. Pathophysiol Haemos Thromb 2003; 33(suppl 1): O14.
54. Lee AYY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M, Rickles FR, Julian JA, Haley S, Kovacs MJ, Gent M. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003; 349: 146-153.
55. Meyer G, Marjanovic Z, Valcke J, Lorcerie B, Gruel Y, Solal-Celigny P, Le Maignan C, Extra JM, Cottu P, Farge D. Comparison of low-molecular-weight-heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled trial. Arch Intern Med 2002; 162: 1729-1735
56. Hull RD, Pineo GF, Mah AF, Brant RF. A randomized trial evaluating long-term molecular weight heparin therapy for three months versus intravenous heparin followed by warfarin sodium. [abstract] Blood 2002; 100: 556
57. Bick RL. Cancer-associated thrombosis. N Engl J Med 2003: 349: 109-111
58. Zacharski LR, Henderson WG, Rickles FR et al. Effect of warfarin on survival in small cell carcinoma of the lung: Veterans Administration study no. 75. JAMA 1981; 245: 831-835
59. Zacharski LR, Henderson WG, Rickles FR et al. Effect of warfarin anticoagulation on survival in carcinoma of the lung, colon, head and neck, and prostate. Final report of VA Cooperative Study 75. Cancer 1984; 53: 2046-2052
60. Daly L. The first international urokinase/warfarin trial in colorectal cancer. Clin Exp Metastasis 1991; 9: 3-11
61. Chahinian AP, Propert KJ, Ware JH et al. A randomized trial of anticoagulation with warfarin and of alternating chemoterapy in extensive small-cell lung cancer by the Cancer and Leukemia Group B. J Clin Oncol 1989; 7: 993-1002
62. Maurer LH, Herndon JE, Hollis DR et al. Randomized trial of chemotherapy and radiation therapy with or without warfarin for limited-stage small-cell lung cancer: a CALGB study. J Clin Oncol 1997; 15: 3378-3387
63. Zacharski LR, Ornstein DL. Venous thrombosis and cancer. N Engl J Med 2000; 343: 1338
64. Sürmer T, Glynn RJ, Lee I-M, Manson JE, Buring JE, Hennekens CH. Aspirin use and colorectal cancer: post-trial follow-up data from the Physicians' Health Study. Ann Intern Med 1998; 128: 713-720
65. Smalley W, Ray WA, Daugherty J, Griffin MR. Use of non-steroidal anti-inflammatory drugs and incidence of colorectal cancer: a population-based study. Arch Intern Med 1999; 159: 161-166
66. Sorensen HT, Friis S, Norgard B, Mellemkjaer L, Blot WJ, McLaughlin JK, Ekbom A, Baron JA. Risk of cancer in a large cohort of non-aspirin NSAID users: a population-based study. Br J Cancer 2003; 88: 1687-1692
67. Steinbach G, Lynch PM, Phillips RS et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000; 342: 1946-1952